Clinical trials: insulin glargine
Diabetes Mellitus, Type 1
Glulisine + Lantus in Type I Patients
To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR 1964) in subjects with type I diabetes…
- Trial name
- NCT00546702
- Testing
- Insuline Glulisine
- Where
- Russia
- Volunteers
- 142 people
- Sponsor
- Sanofi
Type1 Diabetes Mellitus, Type2 Diabetes Mellitus
Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus
- Trial name
- NCT03332849
- Testing
- HM12470
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy Volunteers
Molar Potency Study of HM12460A in Healthy Subjects
This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.
- Trial name
- NCT03330314
- Testing
- HM12460A
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 2 Diabetes
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with…
- Trial name
- NCT00360334
- Testing
- exenatide, insulin glargine
- Where
- 31 sites in United Kingdom
- Volunteers
- 235 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
Diabetes is a disorder of high blood glucose, that tends to get worse; over time, patients need more and more drugs. This pattern is caused by overwork of the body's insulin-producing β-cells, because patients' glucose levels are…
- Trial name
- CHANGE (NCT05040087)
- Testing
- Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Foundation for Atlanta Veterans Education and Research, Inc.
Type2 Diabetes
Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
This is a study to be performed in Qatar that will look at the comparison of glycemic control in patients with type 2 diabetes on insulin glargine U100 with insulin degludec over the Ramadan period, to determine whether better…
- Trial name
- NCT03349840
- Testing
- Insulin Degludec U100, Insulin Glargine
- Where
- Qatar
- Volunteers
- 273 people
- Sponsor
- Weill Cornell Medical College in Qatar
Type 2 Diabetes Mellitus
Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
Premixed insulin-based therapy is a standard insulin treatment strategy in Austria. The widespread use of premixed insulin is explained by high acceptance by health care professionals and patients due to one single product and…
- Trial name
- LixiBIT (NCT02168491)
- Testing
- Lixisenatide, Insulin glargine
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Type 2 Diabetes Mellitus
Insulin Glargine in Type 2 Diabetes Mellitus
Primary objective: To compare efficacy of oral antidiabetics (OAD) combination therapy with either HOE901 insulin analogue once daily or Lispro insulin analogue at mealtime in terms of change in HbA1c (baseline to endpoint).
- Trial name
- NCT00311818
- Testing
- Insulin glargine
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
This study will look into insulin sensitivity (how the body responds to insulin) and effects of meals on type 2 diabetics comparing insulin peglispro to insulin glargine.
- Trial name
- NCT02197520
- Testing
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
COPD, Hyperglycemia
Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards
Patients with chronic obstructive pulmonary disease (COPD) are commonly admitted to hospital with exacerbations of their lung disease.
- Trial name
- IPS2008 (NCT00764556)
- Testing
- Insulin
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- St George's, University of London
Diabetes Mellitus, Type 2
Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)
The primary objective of this study is to compare the percentage of subjects who reach the target HbA1c level (< or = 7.0% at endpoint) and do not experience symptomatic nocturnal hypoglycemia during treatment with insulin…
- Trial name
- NCT00653341
- Testing
- insulin glargine, NPH human insulin
- Where
- 2 sites in United States, Canada
- Volunteers
- 764 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.
The primary objective of the present study is to verify the superiority of Telecare program vs. standard SMBG program in terms of mean HbA1c value (- 0,5%) at end-point.
- Trial name
- NCT00272064
- Testing
- Insulin glulisine, Insulin glargine, Metformin
- Where
- Italy
- Volunteers
- 352 people
- Sponsor
- Sanofi
Type 2 Diabetes, T2D
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who…
- Trial name
- QWINT-1 (NCT05662332)
- Testing
- Insulin Efsitora Alfa, Insulin Glargine
- Where
- 71 sites in United States, Argentina and 2 more
- Volunteers
- 795 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
The study will compare two combination therapies: 1) Combined Basal Insulin Glargine (once a day), Exenatide (twice a day), and Metformin Therapy; or 2) Combined Basal Insulin Glargine (once a day), Bolus Insulin Lispro (three…
- Trial name
- NCT00960661
- Testing
- exenatide, insulin lispro, Metformin
- Where
- 95 sites in Argentina, Belgium and 16 more
- Volunteers
- 1,036 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
Lispro Mix 25 vs. Glargine in Type 2 Diabetics
In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment…
- Trial name
- IOOL (NCT00551356)
- Testing
- Insulin lispro mix 25, Glargine
- Where
- Mexico
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2…
- Trial name
- NCT06688123
- Testing
- SHR-3167, Insulin glargine
- Where
- 2 sites in China
- Volunteers
- 275 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
This will be a randomized, open label, parallel group, multicenter study. There will be two phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of regimens of basal insulin intensified with…
- Trial name
- NCT00467649
- Testing
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Where
- 37 sites in United States
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).
- Trial name
- NCT03260868
- Testing
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Where
- 6 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Sanofi
Type 2 Diabetes
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.
- Trial name
- NCT04605991
- Testing
- LY900014, Insulin Glargine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)
Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®.
- Trial name
- RADIAL (NCT05780151)
- Testing
- Methodological intervention, Toujeo
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 107 people
- Sponsor
- Mira Zuidgeest